ARTICLE | Clinical News

Rexin-G regulatory update

July 14, 2008 7:00 AM UTC

FDA granted Orphan Drug designation for Rexin-G to treat osteosarcoma. The tumor-targeted gene therapy vector bearing a killer gene that blocks the action of human cyclin G1 gene, which is approved in the Philippines to treat intractable cancers, is in separate Phase I/II trials in the U.S. for breast cancer, prostate cancer and sarcomas. ...